Pub Date : 2020-04-13DOI: 10.3760/CMA.J.CN311367-20200316-00148
Feng-hua Xu, X. Qin, Lei Zhang, Fei Wu, Yu Jin, Yan Xu, Caiyuan Liu, Yilin Xiong, Gangping Li, X. Xiang, Yudong Jiang, T. Bai, X. Hou, Jun Song
Objective To analyze the clinical characteristics of gastrointestinal symptoms and liver function injury in patients with coronavirus disease 2019 (COVID-19). Methods From January 23, 2020 to February 29, 2020, medical records of 251 patients with COVID-19 admitted to the West Campus of the Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, were collected. The proportion of the patients with gastrointestinal symptoms including anorexia, nausea and vomit, diarrhea and abdominal pain were analyzed respectively. The patients were divided into common type (76 cases), severe type (65 cases) and critical type (110 cases). The incidence of liver function injury and index of liver function such as total bilirubin (TBil), direct bilirubin (DBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH) and albumin of the patients with different clinical types and with or without gastrointestinal symptoms were analyzed. Student t test, Chi square test and Fisher's exact test were performed for statistical analysis. Results The main gastrointestinal symptoms of patients with COVID-19 were anorexia (33.9%, 85/251), diarrhea (12.0%, 30/251), nausea and vomit (7.6%, 19/251) and abdominal pain (1.2%, 3/251). 143 patients (57.0%) had liver function injury, the rate of liver function injury in critical type patients was 75.5% (83/110), which was higher than that of common type (40.8%, 31/76) and severe type patients (44.6%, 29/65), and the differences were statistically significant (χ2=22.765 and 16.865, both P 0.05). The proportion of liver function injury of patients with gastrointestinal symptoms was 57.8% (67/116), compared with that of liver function injury of patients without gastrointestinal symptoms (56.3%, 76/135), the difference was not statistically significant (P>0.05). The median value of TBil, DBil, ALT, AST, ALP, GGT, LDH and globulin level of critical type patients was 13.5 μmol/L, 4.9 μmol/L, 44.5 U/L and 50.0 U/L, 64.0 U/L, 41.0 U/L, 527.0 U/L and 33.6 g/L respectively. The proportion of critical type patients with TBil level > 34.2 μmol, DBil >13.6 μmol, ALT> 80 U/L and AST> 80 U/L was 7.3% (8/110), 7.3% (8/110), 17.3% (19/110) and 17.3% (19/110), respectively. These results were all higher than those of common type patients (9.5 μmol/L, 2.9 μmol/L, 28.5 U/L, 28.5 U/L, 54.0 U/L, 25.5 U/L, 225.5 U/L and 30.1 g/L, 0, 0, 6.6% (5/76), 2.6% (2/76) ) and severe type patients (10.4 μmol/L, 3.4 μmol/L, 30.0 U/L, 31.0 U/L, 49.0 U/L, 25.0 U/L, 284.0 U/L and 30.7 g/L, 0, 0, 6.2% (4/65), 1.5% (1/65) ), and the differences were statistically significant (Z=-4.264, -5.507,-4.000, -6.558, -3.112, -4.333, -4.858, -3.873, Fisher's exact test, Fisher's exact test, χ2=4.574, 9.620; Z=-3.060, -3.850, -3.923, -5.005, -9.495, -7.651, -3.853, -2.725, Fisher's exact test, Fisher's exact test, χ2=4.425, 10.169; all P 20.0
目的分析2019冠状病毒病(COVID-19)患者胃肠道症状及肝功能损伤的临床特点。方法收集2020年1月23日至2020年2月29日华中科技大学同济医学院协和医院西校区收治的新冠肺炎患者病历251例。分别分析患者出现厌食、恶心呕吐、腹泻、腹痛等胃肠道症状的比例。患者分为普通型(76例)、重症(65例)和危重型(110例)。分析不同临床类型、有无胃肠道症状患者肝功能损伤发生率及肝功能指标如总胆红素(TBil)、直接胆红素(DBil)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)、γ-谷氨酰转肽酶(GGT)、乳酸脱氢酶(LDH)、白蛋白。采用学生t检验、卡方检验和Fisher精确检验进行统计分析。结果新冠肺炎患者的主要胃肠道症状为厌食(33.9%，85/251)、腹泻(12.0%，30/251)、恶心呕吐(7.6%，19/251)和腹痛(1.2%，3/251)。143例(57.0%)患者出现肝功能损伤，危重型患者肝功能损伤率为75.5%(83/110)，高于普通型(40.8%，31/76)和重症(44.6%，29/65)，差异均有统计学意义(χ2=22.765、16.865,P均为0.05)。有胃肠道症状患者肝功能损伤比例为57.8%(67/116)，无胃肠道症状患者肝功能损伤比例为56.3%(76/135)，差异无统计学意义(P>0.05)。危重型患者TBil、DBil、ALT、AST、ALP、GGT、LDH及球蛋白水平中位数分别为13.5 μmol/L、4.9 μmol/L、44.5 μmol/L、50.0 μmol/L、64.0 U/L、41.0 U/L、527.0 U/L、33.6 g/L。TBil > 34.2 μmol、DBil >13.6 μmol、ALT> 80 U/L、AST> 80 U/L的危重型患者比例分别为7.3%(8/110)、7.3%(8/110)、17.3%(19/110)、17.3%(19/110)。这些结果都高于常见病人(9.5μ摩尔/升,2.9μmol / L, 28.5 U / L, 28.5 U / L, 54.0 U / L, 25.5 U / L, 225.5 U / L和30.1 g / L, 0, 0, 6.6%(5/76), 2.6%(2/76))和严重类型的病人(10.4μ摩尔/升,3.4μmol / L, 30.0 U / L, 31.0 U / L, 49.0 U / L, 25.0 U / L, 284.0 U / L和30.7 g / L, 0, 0, 6.2%(4/65), 1.5%(1/65),差异具有统计学意义(Z = -4.264, -5.507, -4.000, -6.558, -3.112, -4.333, -4.858, -3.873,确切概率法,确切概率法,χ2 = 4.574,9.620;Z=-3.060， -3.850， -3.923， -5.005， -9.495， -7.651， -3.853， -2.725，费雪精确检验，χ2=4.425, 10.169;腹泻患者P 20.0 ~ 34.2 μmol/L均高于非腹泻患者(70.0%，21/30 vs 10.9%， 24/221)，差异有统计学意义(Z = -2.182, P = 0.029;χ2 = 62.788, p <0.01)。结论厌食是新冠肺炎患者最常见的消化系统症状，腹泻、恶心呕吐、腹痛发生率较低。危重型患者肝功能损伤发生率高。胃肠道症状与肝功能损伤无明显相关性。腹泻患者白蛋白水平较低。关键词:2019冠状病毒病;腹泻;胃肠道症状;肝功能;白蛋白
{"title":"Clinical characteristics of gastrointestinal symptoms and liver function injury in patients with coronavirus disease 2019","authors":"Feng-hua Xu, X. Qin, Lei Zhang, Fei Wu, Yu Jin, Yan Xu, Caiyuan Liu, Yilin Xiong, Gangping Li, X. Xiang, Yudong Jiang, T. Bai, X. Hou, Jun Song","doi":"10.3760/CMA.J.CN311367-20200316-00148","DOIUrl":"https://doi.org/10.3760/CMA.J.CN311367-20200316-00148","url":null,"abstract":"Objective \u0000To analyze the clinical characteristics of gastrointestinal symptoms and liver function injury in patients with coronavirus disease 2019 (COVID-19). \u0000 \u0000 \u0000Methods \u0000From January 23, 2020 to February 29, 2020, medical records of 251 patients with COVID-19 admitted to the West Campus of the Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, were collected. The proportion of the patients with gastrointestinal symptoms including anorexia, nausea and vomit, diarrhea and abdominal pain were analyzed respectively. The patients were divided into common type (76 cases), severe type (65 cases) and critical type (110 cases). The incidence of liver function injury and index of liver function such as total bilirubin (TBil), direct bilirubin (DBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH) and albumin of the patients with different clinical types and with or without gastrointestinal symptoms were analyzed. Student t test, Chi square test and Fisher's exact test were performed for statistical analysis. \u0000 \u0000 \u0000Results \u0000The main gastrointestinal symptoms of patients with COVID-19 were anorexia (33.9%, 85/251), diarrhea (12.0%, 30/251), nausea and vomit (7.6%, 19/251) and abdominal pain (1.2%, 3/251). 143 patients (57.0%) had liver function injury, the rate of liver function injury in critical type patients was 75.5% (83/110), which was higher than that of common type (40.8%, 31/76) and severe type patients (44.6%, 29/65), and the differences were statistically significant (χ2=22.765 and 16.865, both P 0.05). The proportion of liver function injury of patients with gastrointestinal symptoms was 57.8% (67/116), compared with that of liver function injury of patients without gastrointestinal symptoms (56.3%, 76/135), the difference was not statistically significant (P>0.05). The median value of TBil, DBil, ALT, AST, ALP, GGT, LDH and globulin level of critical type patients was 13.5 μmol/L, 4.9 μmol/L, 44.5 U/L and 50.0 U/L, 64.0 U/L, 41.0 U/L, 527.0 U/L and 33.6 g/L respectively. The proportion of critical type patients with TBil level > 34.2 μmol, DBil >13.6 μmol, ALT> 80 U/L and AST> 80 U/L was 7.3% (8/110), 7.3% (8/110), 17.3% (19/110) and 17.3% (19/110), respectively. These results were all higher than those of common type patients (9.5 μmol/L, 2.9 μmol/L, 28.5 U/L, 28.5 U/L, 54.0 U/L, 25.5 U/L, 225.5 U/L and 30.1 g/L, 0, 0, 6.6% (5/76), 2.6% (2/76) ) and severe type patients (10.4 μmol/L, 3.4 μmol/L, 30.0 U/L, 31.0 U/L, 49.0 U/L, 25.0 U/L, 284.0 U/L and 30.7 g/L, 0, 0, 6.2% (4/65), 1.5% (1/65) ), and the differences were statistically significant (Z=-4.264, -5.507,-4.000, -6.558, -3.112, -4.333, -4.858, -3.873, Fisher's exact test, Fisher's exact test, χ2=4.574, 9.620; Z=-3.060, -3.850, -3.923, -5.005, -9.495, -7.651, -3.853, -2.725, Fisher's exact test, Fisher's exact test, χ2=4.425, 10.169; all P 20.0 ","PeriodicalId":10009,"journal":{"name":"中华消化杂志","volume":"226 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80126514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-30DOI: 10.3760/CMA.J.CN311367-20200315-00141
Yuanmei Guo, Jixiang Zhang, Qiutang Xiong, Jiao Li, Mengyao Ji, P. An, Xiaoguang Lyu, Fei Liao, Wenhao Su, W. Dong
Objective To retrospectively analyze the clinical characteristics of patients with coronavirus disease 2019 (COVID-19) accompanied with diarrhea. Methods From January 11 to February 6 in 2020, the clinical data of 663 patients diagnosed with COVID-19 admitted to Renmin Hospital of Wuhan University were collected. According to whether with diarrhea, the patients were divided into with diarrhea group and without diarrhea group. The differences in general condition, clinical manifestation, chest computed tomography (CT), laboratory findings, disease severity and death situation between two groups were compared. Chi-square test, Fisher exact test and Mann-Whitney U test were performed for statistical analysis. Results Among 663 COVID-19 patients, 70 (10.6%) patients accompanied with diarrhea. The ratio of fatigue and increased lactate dehydrogenase (LDH) of with diarrhea group were higher than those of without diarrhea group (58.6%, 41/70 vs. 28.2%, 167/593; and 64.2%, 43/67 vs. 50.4%, 277/550), and the differences were statistically significant (χ2=26.891 and 4.566, both P 0.05). There were no statistically significant differences in the ratio of mild and normal type, severe type and critical type between diarrhea group and without diarrhea group (35.7%, 25/70 vs. 38.6%, 229/593; 50.0%, 35/70 vs. 47.2%, 280/593; and 14.3%, 10/70 vs. 14.2%, 84/593, respectively) (χ2=0.240, P=0.887). There were no statistically significant differences in the ratio of death of each corresponding mild and normal type, severe type and critical type between diarrhea group and without diarrhea group (0 vs. 0.5%, 3/593; 0 vs 0 and 1.4%, 1/70 vs. 3.5%, 21/593) (Fisher exact test, all P>0.05). Conclusions Patients with COVID-19 accompanied with diarrhea are more likely to have fatigue and increased LDH. Diarrhea is not significantly correlated with the disease severity of patients with COVID-19. Key words: COVID-19; Diarrhea; Clinical characteristics; Disease severity
目的回顾性分析2019冠状病毒病(COVID-19)合并腹泻患者的临床特点。方法收集2020年1月11日至2月6日武汉大学人民医院收治的663例新冠肺炎确诊患者的临床资料。根据有无腹泻分为有腹泻组和无腹泻组。比较两组患者一般情况、临床表现、胸部CT、实验室检查、病情严重程度及死亡情况的差异。采用卡方检验、Fisher精确检验和Mann-Whitney U检验进行统计学分析。结果663例新冠肺炎患者中有70例(10.6%)伴有腹泻。腹泻组的疲劳率和乳酸脱氢酶(LDH)升高率高于未腹泻组(58.6%，41/70比28.2%，167/593;64.2%(43/67比50.4%，277/550)，差异有统计学意义(χ2=26.891、4.566,P均为0.05)。轻度型与正常型、重度型与危重型的比例，腹泻组与无腹泻组比较差异无统计学意义(35.7%，25/70比38.6%，229/593;50.0%， 35/70 vs. 47.2%， 280/593;14.3%， 10/70比14.2%，84/593)(χ2=0.240, P=0.887)。腹泻组与无腹泻组各对应轻、正常型、重度、危重型的死亡率比较，差异均无统计学意义(0比0.5%，3/593;0比0和1.4%，1/70比3.5%，21/593)(Fisher精确检验，P均>0.05)。结论COVID-19合并腹泻患者更容易出现疲劳和LDH升高。腹泻与COVID-19患者病情严重程度无显著相关性。关键词:COVID-19;腹泻;临床特点;疾病严重程度
{"title":"Clinical characteristics of 70 patients with coronavirus disease 2019 accompanied with diarrhea","authors":"Yuanmei Guo, Jixiang Zhang, Qiutang Xiong, Jiao Li, Mengyao Ji, P. An, Xiaoguang Lyu, Fei Liao, Wenhao Su, W. Dong","doi":"10.3760/CMA.J.CN311367-20200315-00141","DOIUrl":"https://doi.org/10.3760/CMA.J.CN311367-20200315-00141","url":null,"abstract":"Objective \u0000To retrospectively analyze the clinical characteristics of patients with coronavirus disease 2019 (COVID-19) accompanied with diarrhea. \u0000 \u0000 \u0000Methods \u0000From January 11 to February 6 in 2020, the clinical data of 663 patients diagnosed with COVID-19 admitted to Renmin Hospital of Wuhan University were collected. According to whether with diarrhea, the patients were divided into with diarrhea group and without diarrhea group. The differences in general condition, clinical manifestation, chest computed tomography (CT), laboratory findings, disease severity and death situation between two groups were compared. Chi-square test, Fisher exact test and Mann-Whitney U test were performed for statistical analysis. \u0000 \u0000 \u0000Results \u0000Among 663 COVID-19 patients, 70 (10.6%) patients accompanied with diarrhea. The ratio of fatigue and increased lactate dehydrogenase (LDH) of with diarrhea group were higher than those of without diarrhea group (58.6%, 41/70 vs. 28.2%, 167/593; and 64.2%, 43/67 vs. 50.4%, 277/550), and the differences were statistically significant (χ2=26.891 and 4.566, both P 0.05). There were no statistically significant differences in the ratio of mild and normal type, severe type and critical type between diarrhea group and without diarrhea group (35.7%, 25/70 vs. 38.6%, 229/593; 50.0%, 35/70 vs. 47.2%, 280/593; and 14.3%, 10/70 vs. 14.2%, 84/593, respectively) (χ2=0.240, P=0.887). There were no statistically significant differences in the ratio of death of each corresponding mild and normal type, severe type and critical type between diarrhea group and without diarrhea group (0 vs. 0.5%, 3/593; 0 vs 0 and 1.4%, 1/70 vs. 3.5%, 21/593) (Fisher exact test, all P>0.05). \u0000 \u0000 \u0000Conclusions \u0000Patients with COVID-19 accompanied with diarrhea are more likely to have fatigue and increased LDH. Diarrhea is not significantly correlated with the disease severity of patients with COVID-19. \u0000 \u0000 \u0000Key words: \u0000COVID-19; Diarrhea; Clinical characteristics; Disease severity","PeriodicalId":10009,"journal":{"name":"中华消化杂志","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90952716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-27DOI: 10.3760/CMA.J.CN311367-20200317-00152
Ling Yang, Weifen Xie
2019 coronavirus disease(COVID-19) as a novel infectious respiratory disease, has become pandemic worldwide. The clinical manifestation of COVID-19 is complicated and varied. In addition to lung injury, liver is also one of the important organs to be affected. Abnormal liver function is common in the various stage of COVID-19. It is urgent to pay attention to the role of hypoxic-ischemia-reperfusion injury and drug-induced liver injury. Careful differentiation and precise management of COVID-19 associated liver injury are critical to reduce the incidence rate, improve the survival rate and shorten hospital stays. In the future to strengthen the pathophysiologic, therapeutic and prognostic research of COVID-19 associated liver injury is also required. Key words: 2019 coronavirus disease; Liver injury; Hepatic hypoxic-ischemia-reperfusion injury; Drug-induced liver injury
{"title":"Pay attention to the etiological analysis and management of 2019 coronavirus disease associated liver injury","authors":"Ling Yang, Weifen Xie","doi":"10.3760/CMA.J.CN311367-20200317-00152","DOIUrl":"https://doi.org/10.3760/CMA.J.CN311367-20200317-00152","url":null,"abstract":"2019 coronavirus disease(COVID-19) as a novel infectious respiratory disease, has become pandemic worldwide. The clinical manifestation of COVID-19 is complicated and varied. In addition to lung injury, liver is also one of the important organs to be affected. Abnormal liver function is common in the various stage of COVID-19. It is urgent to pay attention to the role of hypoxic-ischemia-reperfusion injury and drug-induced liver injury. Careful differentiation and precise management of COVID-19 associated liver injury are critical to reduce the incidence rate, improve the survival rate and shorten hospital stays. In the future to strengthen the pathophysiologic, therapeutic and prognostic research of COVID-19 associated liver injury is also required. \u0000 \u0000Key words: \u00002019 coronavirus disease; Liver injury; Hepatic hypoxic-ischemia-reperfusion injury; Drug-induced liver injury","PeriodicalId":10009,"journal":{"name":"中华消化杂志","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75548057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mechanisms and potential treatments for gastrointestinal symptoms in coronavirus disease 2019, severe acute respiratory syndrome, and Middle East respiratory syndrome","authors":"Cao Li, Teng Liu, Shanshan Guo","doi":"10.3760/CMA.J.ISSN.0254-1432.2020.03.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.0254-1432.2020.03.008","url":null,"abstract":"新型冠状病毒肺炎(COVID-19)以肺部表现为主，同时感染胃肠道，引起包括恶心、呕吐、腹泻等消化系统症状。现结合现有指南和国内外文献资料，探讨了COVID-19、严重急性呼吸综合征、中东呼吸综合征伴发胃肠道症状的临床特点、流行病学特征和发病机制，以及抗菌药物、微生态制剂、血管紧张素转换酶2抑制剂在COVID-19肠道损害治疗中的作用机制和潜在价值，以期为临床工作者预防和治疗COVID-19肠道损害提供参考。","PeriodicalId":10009,"journal":{"name":"中华消化杂志","volume":"1 1","pages":"176-179"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83059137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Considerations and suggestions on clinical research for coronavirus disease 2019","authors":"Xu Jin","doi":"10.3760/CMA.J.ISSN.0254-1432.2020.03.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.0254-1432.2020.03.002","url":null,"abstract":"新型冠状病毒肺炎(COVID-19)疫情之下迫切需要找到有效的治疗手段来对抗这种疾病。一系列候选治疗已经进入临床试验或正处于准备阶段。鉴于找到有效药物的紧迫性，在循证医学临床研究设计规范与准则的基础上，提出除了临床随机对照试验外，可以采用实验性的整群随机对照试验、阶梯设计，以及观察性的病例-时间-对照研究等设计类型，开展COVID-19治疗药物的临床研究，并且强调顶层科学设计、有序规范开展，避免重复研究，阻止低效或设计方案存在偏倚的临床研究。呼吁构建标准统一的信息系统，设立明确的COVID-19临床数据标准和数据收集模式，以在常规医疗环境下形成COVID-19的病例队列，开展比较效果研究，切实解决并促进临床研究人员更好地共享、交换信息，提高研究效率。","PeriodicalId":10009,"journal":{"name":"中华消化杂志","volume":"29 5","pages":"148-150"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72634836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-15DOI: 10.3760/CMA.J.ISSN.0254-1432.2020.03.010
Jie Liu, Chuan Han, Jian Zhang, Xianmin Xue, Y. Nie, Yongquan Shi
Objective To analyze the difference of psychosocial characteristics in patients with chronic gastritis. Methods From June to December 2018, a total of 300 patients with chronic gastritis visited Xijing Hospital were consecutively enrolled. The patients were divided into chronic non-atrophic gastritis (CNAG) group, chronic atrophic gastritis (CAG) group and CAG with intestinal metaplasia group, with 100 cases in each group. Hamilton anxiety scale (HAMA), Hamilton depression scale (HAMD), living events scale (LES) and Eysenck personality questionnaire (EPQ) were used for evaluation and analysis. Chi square test, analysis of variance, nonparametric rank sum test and Kruskal Wallis H test were used for statistical analysis. Results The incidences of anxiety of the CAG group and the CAG with intestinal metaplasia group were both significantly higher than that of the CNAG group (64.0%, 64/100; 53.0%, 53/100; and 34.0%, 34/100; respectively), and the differences were statistically significant (χ2=0.007 and 0.001, both P 56.7) of etraversion or introversion and concealment in CAG group and the CAG with intestinal metaplasia group were higher than those in the CNAG group (48.0%, 48/100; 23.0%, 23/100; 4.0%, 4/100 and 46.0%, 46/100; 21.0%, 21/100 and 7.0%, 7/100, respectively), and the differences were statistically significant (χ2=0.001, 0.001, 0.001 and 0.004, all P<0.01). Conclusions Anxiety is associated with CAG and intestinal metaplasia, while depression is associated with intestinal metaplasia. In male patients and patients under 50 years old, depression, negative event and high psychiatric stress are more significantly related to intestinal metaplasia. The mental characteristics of extroversion, emotional instability, psychoticism and concealment are closely associated with CAG. Key words: Chronic gastritis; Atrophy; Intestinal metaplasia; Psychological characteristic; Mental characteristic
{"title":"Psychoanalysis of 300 patients with chronic gastritis","authors":"Jie Liu, Chuan Han, Jian Zhang, Xianmin Xue, Y. Nie, Yongquan Shi","doi":"10.3760/CMA.J.ISSN.0254-1432.2020.03.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.0254-1432.2020.03.010","url":null,"abstract":"Objective \u0000To analyze the difference of psychosocial characteristics in patients with chronic gastritis. \u0000 \u0000 \u0000Methods \u0000From June to December 2018, a total of 300 patients with chronic gastritis visited Xijing Hospital were consecutively enrolled. The patients were divided into chronic non-atrophic gastritis (CNAG) group, chronic atrophic gastritis (CAG) group and CAG with intestinal metaplasia group, with 100 cases in each group. Hamilton anxiety scale (HAMA), Hamilton depression scale (HAMD), living events scale (LES) and Eysenck personality questionnaire (EPQ) were used for evaluation and analysis. Chi square test, analysis of variance, nonparametric rank sum test and Kruskal Wallis H test were used for statistical analysis. \u0000 \u0000 \u0000Results \u0000The incidences of anxiety of the CAG group and the CAG with intestinal metaplasia group were both significantly higher than that of the CNAG group (64.0%, 64/100; 53.0%, 53/100; and 34.0%, 34/100; respectively), and the differences were statistically significant (χ2=0.007 and 0.001, both P 56.7) of etraversion or introversion and concealment in CAG group and the CAG with intestinal metaplasia group were higher than those in the CNAG group (48.0%, 48/100; 23.0%, 23/100; 4.0%, 4/100 and 46.0%, 46/100; 21.0%, 21/100 and 7.0%, 7/100, respectively), and the differences were statistically significant (χ2=0.001, 0.001, 0.001 and 0.004, all P<0.01). \u0000 \u0000 \u0000Conclusions \u0000Anxiety is associated with CAG and intestinal metaplasia, while depression is associated with intestinal metaplasia. In male patients and patients under 50 years old, depression, negative event and high psychiatric stress are more significantly related to intestinal metaplasia. The mental characteristics of extroversion, emotional instability, psychoticism and concealment are closely associated with CAG. \u0000 \u0000 \u0000Key words: \u0000Chronic gastritis; Atrophy; Intestinal metaplasia; Psychological characteristic; Mental characteristic","PeriodicalId":10009,"journal":{"name":"中华消化杂志","volume":"19 1","pages":"186-191"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84637967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Digestive system manifestations and analysis of disease severity in 54 patients with coronavirus disease 2019","authors":"Jihua Shi, Yiran Wang, Wenbin Li, Rui Gang, Xiao Liu, L. Xu","doi":"10.3760/CMA.J.ISSN.0254-1432.2020.03.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.0254-1432.2020.03.006","url":null,"abstract":"本研究通过回顾性分析2020年2月9至29日华中科技大学附属同济医院中法新城院区隔离病房北京医院国家援鄂抗疫医疗队收治的54例新型冠状病毒肺炎(COVID-19)患者的临床资料，比较不同临床分型患者的基本临床特征、入院时外周血生物化学指标检测结果，以及炎症指标如IL-6、超敏C-反应蛋白(HsCRP)和铁蛋白水平。结果发现COVID-19患者的消化系统症状并不少见，以腹泻(22.2%)和恶心(14.8%)为主，普通型患者的腹泻比例更是高达26.3%(10/38)，仅次于常见症状发热、乏力和咳嗽；患者外周血LDH、D-二聚体水平和炎症指标IL-6、HsCRP水平均与临床疾病分型相关，能够提示COVID-19的严重程度。","PeriodicalId":10009,"journal":{"name":"中华消化杂志","volume":"49 1","pages":"167-170"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73781627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Expert recommendations on pathological diagnosis of inflammatory bowel disease","authors":"Shuyuan Xiao, Z. Ye, Min Chen, Weixun Zhou, Xueying Shi, Ze Li, Fei Yuan, Zhinong Jiang, Jing Sun, Xinying Wang","doi":"10.3760/CMA.J.ISSN.0254-1432.2020.03.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.0254-1432.2020.03.009","url":null,"abstract":"病理在IBD诊断和鉴别诊断中的作用受到广泛关注，但仍存在观念、认识和实践上的问题和误区。本专家建议强调肠道炎症性疾病的病理诊断思路应从识别病变模式出发，每种模式提示一类可能的鉴别诊断。慢性肠炎是IBD的组织学模式，但IBD的诊断必须建立在慢性肠炎模式结合临床和系统性规范活组织检查的基础上。针对病理医师在IBD诊断和鉴别诊断中常引起困惑的问题提出专家建议，包括CD与UC、CD与肠结核、CD与肠道血管疾病，以及IBD与感染性肠炎之间的鉴别，也建议病理医师通过对诊断的病例主动随访反馈，在实践中不断积累诊断经验。","PeriodicalId":10009,"journal":{"name":"中华消化杂志","volume":"29 1","pages":"180-185"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83078627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-15DOI: 10.3760/CMA.J.ISSN.0254-1432.2020.03.003
Dan Fang, Jingdong Ma, Jia-Lun Guan, Mu-ru Wang, Yang Song, D. Tian, Pei-Yuan Li
Objective To study the manifestations of digestive system of hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China, and to provide a reference for disease control and treatment. Methods The data of hospitalized patients with COVID-19 in the Sino-French Branch of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 27 to February 14, 2020 were retrospectively analyzed, which included general information, positive rate of nucleic acid test, severity of disease, incubation period, initial symptoms and manifestations of digestive system. The general information, positive rate of nucleic acid detection, and manifestations of digestive system were compared between critical patients who required non-invasive or invasive assisted ventilation (critical group) and non-critical patients without assisted ventilation (non-critical group). Continuous corrected Chi-square test and independent sample median Chi-square test were used for statistical analysis. Results Among the 305 patients, there were 146 males (47.9%) and 159 females (52.1%), and the median age was 57 years old. Nucleic acid assay of nasopharyngeal swabs or pharyngeal swabs were positive in 84.1% (228/271) patients including 46 patients (15.1%) of critical group and 259 patients (84.9%) of non-critical group. The incubation period was one to fifteen days, and the median period was six days. The initial symptoms were mainly fever (81.1%, 163/201), cough (39.3%, 79/201), fatigue (54.7%, 110/201), and loss of appetite (50.2%, 101/201). In one to ten days after the disease onset, 79.1% (159/201) of patients developed gastrointestinal symptoms including nausea (29.4%, 59/201), vomiting (15.9%, 32/201), or abdominal pain (6.0%, 12/201). 49.5% (146/295) of patients had diarrhea, with a median time of 3.3 days, (3.3±1.6) times per day, and a duration of (4.1±2.5) days. After excluding possible drug-related diarrhea, the incidence of diarrhea was still 22.2%. Only 6.9% (4/58) of patients had positive fecal leukocytes or fecal occult blood test. Alanine aminotrans ferase (ALT), aspartate aminotransferase (AST), or total bilirubin (TBil) increased in 39.1% (119/304) of patients on admission. Patients with ALT or AST ≥ 80 U/L only accounted for 7.9% (24/304) and 6.3% (19/304), respectively. About 2.0% (6/304) of patients also had increased TBil level, and the average level was (37.4±21.1) μmol/L. The median age of critical group was older than that of non-critical group (65 years vs. 56 years), the proportion of patients with abnormal liver function and slightly increased AST (40- 0.05). Conclusions The manifestation of digestive system of hospitalized COVID-19 patients in Wuhan is significant, the proportion of patients with diarrhea and abnormal aminotransferase level is high. And on admission the proportion of patients with abnormal liver function of critical group is higher than that of non-critical group, which w
{"title":"Manifestations of digestive system of hospitalized patients with coronavirus disease 2019 in Wuhan, China: a single-center descriptive study","authors":"Dan Fang, Jingdong Ma, Jia-Lun Guan, Mu-ru Wang, Yang Song, D. Tian, Pei-Yuan Li","doi":"10.3760/CMA.J.ISSN.0254-1432.2020.03.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.0254-1432.2020.03.003","url":null,"abstract":"Objective \u0000To study the manifestations of digestive system of hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China, and to provide a reference for disease control and treatment. \u0000 \u0000 \u0000Methods \u0000The data of hospitalized patients with COVID-19 in the Sino-French Branch of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 27 to February 14, 2020 were retrospectively analyzed, which included general information, positive rate of nucleic acid test, severity of disease, incubation period, initial symptoms and manifestations of digestive system. The general information, positive rate of nucleic acid detection, and manifestations of digestive system were compared between critical patients who required non-invasive or invasive assisted ventilation (critical group) and non-critical patients without assisted ventilation (non-critical group). Continuous corrected Chi-square test and independent sample median Chi-square test were used for statistical analysis. \u0000 \u0000 \u0000Results \u0000Among the 305 patients, there were 146 males (47.9%) and 159 females (52.1%), and the median age was 57 years old. Nucleic acid assay of nasopharyngeal swabs or pharyngeal swabs were positive in 84.1% (228/271) patients including 46 patients (15.1%) of critical group and 259 patients (84.9%) of non-critical group. The incubation period was one to fifteen days, and the median period was six days. The initial symptoms were mainly fever (81.1%, 163/201), cough (39.3%, 79/201), fatigue (54.7%, 110/201), and loss of appetite (50.2%, 101/201). In one to ten days after the disease onset, 79.1% (159/201) of patients developed gastrointestinal symptoms including nausea (29.4%, 59/201), vomiting (15.9%, 32/201), or abdominal pain (6.0%, 12/201). 49.5% (146/295) of patients had diarrhea, with a median time of 3.3 days, (3.3±1.6) times per day, and a duration of (4.1±2.5) days. After excluding possible drug-related diarrhea, the incidence of diarrhea was still 22.2%. Only 6.9% (4/58) of patients had positive fecal leukocytes or fecal occult blood test. Alanine aminotrans ferase (ALT), aspartate aminotransferase (AST), or total bilirubin (TBil) increased in 39.1% (119/304) of patients on admission. Patients with ALT or AST ≥ 80 U/L only accounted for 7.9% (24/304) and 6.3% (19/304), respectively. About 2.0% (6/304) of patients also had increased TBil level, and the average level was (37.4±21.1) μmol/L. The median age of critical group was older than that of non-critical group (65 years vs. 56 years), the proportion of patients with abnormal liver function and slightly increased AST (40- 0.05). \u0000 \u0000 \u0000Conclusions \u0000The manifestation of digestive system of hospitalized COVID-19 patients in Wuhan is significant, the proportion of patients with diarrhea and abnormal aminotransferase level is high. And on admission the proportion of patients with abnormal liver function of critical group is higher than that of non-critical group, which w","PeriodicalId":10009,"journal":{"name":"中华消化杂志","volume":"40 1","pages":"151-156"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86980216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-15DOI: 10.3760/CMA.J.ISSN.0254-1432.2020.03.011
Mengyu Sun, C. Wan, Mengnan Lyu, Yan Song, R. Ma, Wen-tian Liu
Objective To observe the preventive effects of infliximab in autoimmune hepatitis (AIH) and to explore its mechanism. Methods The mice AIH model was established by injecting concanavalin A (Con-A) into the caudal vein. Forty mice were divided into prevention group and control group, with 20 mice in each group. The mice of prevention group were injected intravenously with infliximab (20 mg/kg) one hour before Con-A injection and the mice of control group were administrated with 200 μL phosphate buffered saline (PBS). Serum was collected 3, 8, 12 and 24 h after Con-A/PBS injection. The serum level of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) was detected by colorimetry. The level of cytokine interleukin (IL)-6, IL-1β, interferon gamma (IFN-γ), IL-4, IL-17A, IL-10 and chemokine C-X-C motif ligand 10 (CXCL10) was measured by enzyme-linked immunosorbent assay (ELISA). Liver samples were taken 12 h after Con-A/PBS injection for hematoxylin-eosin staining. Liver infiltrated lymphocytes were assessed by flow cytometry. The expression of T-box transcription factor 21 (TBX21), GATA binding protein 3 (GATA3), RAR related orphan receptor C (RORC) and CXCL10 at mRNA level was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). The expression of CXCL10 in liver was detected by Western blotting. Paired t test and one-way analysis of variance were used for statistic analysis. Results At 8, 12, and 24 h after Con-A injection, the serum ALT level, AST level, IL-1β and IFN-γ of prevention group were all lower than those of control group ((545.8±190.3) U/L vs. (865.8±237.7) U/L, (947.6±267.9) U/L vs. (1 448.0±403.5) U/L, (508.6±131.1) U/L vs. (976.6±207.6) U/L; (620.7±132.0) U/L vs. (952.9±106.8) U/L, (801.6±212.0) U/L vs. (1 424.8±236.0) U/L, (632.1±117.8) U/L vs. (1 008.3±187.5) U/L; (31.38±10.12) ng/L vs. (48.12±11.53) ng/L, (39.34±11.40) ng/L vs. (60.00±14.17) ng/L, (29.49±8.22) ng/L vs. (46.89±5.50) ng/L; and (432.93±66.82) ng/L vs. (674.66±97.88) ng/L, (655.09±169.17) ng/L vs. (937.90±166.36) ng/L, (263.40±54.97) ng/L vs. (410.74±86.64) ng/L), and the differences were statistically significant (t = 2.350, 2.308, 4.263, 4.374, 4.860, 3.806, 2.440, 2.541, 3.939, 4.560, 2.660 and 3.210; all P 0.05). Conclusions Infliximab has certain preventive effects in mice AIH model, which may be achieved by antagonizing TNF-α and decreasing the expression of CXCL10 in liver, reducing the infiltration of T-helper 1 cells and CD8+ T cells into liver, and by reducing T lymphocyte activation induced by inflammatory cytokines thus alleviating the damage of T lymphocytes to hepatocytes. Key words: Hepatitis, autoimmune; Infliximab; C-X-C motif chemokine ligand 10; Mice
目的观察英夫利昔单抗对自身免疫性肝炎(AIH)的预防作用，并探讨其作用机制。方法采用尾静脉注射刀豆蛋白A (cona)建立小鼠AIH模型。将40只小鼠分为预防组和对照组，每组20只。预防组小鼠在注射Con-A前1 h静脉注射英夫利昔单抗(20 mg/kg)，对照组小鼠灌胃200 μL磷酸缓冲盐水(PBS)。注射Con-A/PBS后3、8、12、24 h采集血清。采用比色法检测血清谷草转氨酶(AST)和丙氨酸转氨酶(ALT)水平。采用酶联免疫吸附法(ELISA)检测细胞因子白介素(IL)-6、IL-1β、干扰素γ (IFN-γ)、IL-4、IL- 17a、IL-10和趋化因子C-X-C基序配体10 (CXCL10)的水平。注射Con-A/PBS后12 h取肝脏标本进行苏木精-伊红染色。流式细胞术检测肝脏浸润淋巴细胞。采用实时荧光定量聚合酶链式反应(qRT-PCR)检测T-box转录因子21 (TBX21)、GATA结合蛋白3 (GATA3)、RAR相关孤儿受体C (RORC)和CXCL10 mRNA水平的表达。Western blotting检测CXCL10在肝脏中的表达。采用配对t检验和单因素方差分析进行统计分析。结果Con-A注射后8、12、24 h，预防组血清ALT水平、AST水平、IL-1β、IFN-γ均低于对照组((545.8±190.3)U/L比(865.8±237.7)U/L，(947.6±267.9)U/L比(1 448.0±403.5)U/L，(508.6±131.1)U/L比(976.6±207.6)U/L;(620.7±132.0)U / L和(952.9±106.8)/ L, U / L(801.6±212.0)和(424.8±236.0)U / L, U / L(632.1±117.8)和(008.3±187.5)U / L;(31.38±10.12)ng / L和(48.12±11.53)ng / L ng / L(39.34±11.40)和(60.00±14.17)ng / L ng / L(29.49±8.22)和(46.89±5.50)ng / L;(432.93±66.82)ng/L vs(674.66±97.88)ng/L，(655.09±169.17)ng/L vs(937.90±166.36)ng/L，(263.40±54.97)ng/L vs(410.74±86.64)ng/L)，差异均有统计学意义(t = 2.350、2.308、4.263、4.374、4.860、3.806、2.440、2.541、3.939、4.560、2.660、3.210;P < 0.05)。结论英夫利昔单抗对小鼠AIH模型具有一定的预防作用，其机制可能是拮抗TNF-α，降低肝脏中CXCL10的表达，减少T-辅助性1细胞和CD8+ T细胞向肝脏的浸润，减少炎症因子诱导的T淋巴细胞活化，从而减轻T淋巴细胞对肝细胞的损伤。关键词:肝炎;自身免疫;英夫利昔单抗;C-X-C基序趋化因子配体;老鼠
{"title":"Mechanism of infliximab in preventing autoimmune hepatitis in mice model","authors":"Mengyu Sun, C. Wan, Mengnan Lyu, Yan Song, R. Ma, Wen-tian Liu","doi":"10.3760/CMA.J.ISSN.0254-1432.2020.03.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.0254-1432.2020.03.011","url":null,"abstract":"Objective \u0000To observe the preventive effects of infliximab in autoimmune hepatitis (AIH) and to explore its mechanism. \u0000 \u0000 \u0000Methods \u0000The mice AIH model was established by injecting concanavalin A (Con-A) into the caudal vein. Forty mice were divided into prevention group and control group, with 20 mice in each group. The mice of prevention group were injected intravenously with infliximab (20 mg/kg) one hour before Con-A injection and the mice of control group were administrated with 200 μL phosphate buffered saline (PBS). Serum was collected 3, 8, 12 and 24 h after Con-A/PBS injection. The serum level of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) was detected by colorimetry. The level of cytokine interleukin (IL)-6, IL-1β, interferon gamma (IFN-γ), IL-4, IL-17A, IL-10 and chemokine C-X-C motif ligand 10 (CXCL10) was measured by enzyme-linked immunosorbent assay (ELISA). Liver samples were taken 12 h after Con-A/PBS injection for hematoxylin-eosin staining. Liver infiltrated lymphocytes were assessed by flow cytometry. The expression of T-box transcription factor 21 (TBX21), GATA binding protein 3 (GATA3), RAR related orphan receptor C (RORC) and CXCL10 at mRNA level was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). The expression of CXCL10 in liver was detected by Western blotting. Paired t test and one-way analysis of variance were used for statistic analysis. \u0000 \u0000 \u0000Results \u0000At 8, 12, and 24 h after Con-A injection, the serum ALT level, AST level, IL-1β and IFN-γ of prevention group were all lower than those of control group ((545.8±190.3) U/L vs. (865.8±237.7) U/L, (947.6±267.9) U/L vs. (1 448.0±403.5) U/L, (508.6±131.1) U/L vs. (976.6±207.6) U/L; (620.7±132.0) U/L vs. (952.9±106.8) U/L, (801.6±212.0) U/L vs. (1 424.8±236.0) U/L, (632.1±117.8) U/L vs. (1 008.3±187.5) U/L; (31.38±10.12) ng/L vs. (48.12±11.53) ng/L, (39.34±11.40) ng/L vs. (60.00±14.17) ng/L, (29.49±8.22) ng/L vs. (46.89±5.50) ng/L; and (432.93±66.82) ng/L vs. (674.66±97.88) ng/L, (655.09±169.17) ng/L vs. (937.90±166.36) ng/L, (263.40±54.97) ng/L vs. (410.74±86.64) ng/L), and the differences were statistically significant (t = 2.350, 2.308, 4.263, 4.374, 4.860, 3.806, 2.440, 2.541, 3.939, 4.560, 2.660 and 3.210; all P 0.05). \u0000 \u0000 \u0000Conclusions \u0000Infliximab has certain preventive effects in mice AIH model, which may be achieved by antagonizing TNF-α and decreasing the expression of CXCL10 in liver, reducing the infiltration of T-helper 1 cells and CD8+ T cells into liver, and by reducing T lymphocyte activation induced by inflammatory cytokines thus alleviating the damage of T lymphocytes to hepatocytes. \u0000 \u0000 \u0000Key words: \u0000Hepatitis, autoimmune; Infliximab; C-X-C motif chemokine ligand 10; Mice","PeriodicalId":10009,"journal":{"name":"中华消化杂志","volume":"25 1","pages":"192-198"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82851542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：